Latest Breaking News On - Biotech breakthrough awards - Page 2 : comparemela.com

Gracell Biotechnologies Presents Updated Clinical Data From Fastcar-T GC012F Demonstrating Deep And Durable Responses In Newly Diagnosed Multiple Myel

Gracell Biotechnologies Presents Updated Clinical Data From Fastcar-T GC012F Demonstrating Deep And Durable Responses In Newly Diagnosed Multiple Myel
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesWendy liFierce life sciences innovationGracell biotechnologies incAmerican society of hematologyAmerican society for hematologyInternational staging systemAmerican societyAnnual meetingChief medical officerRevised international staging systemInvestigational new drugBiotech innovationLife sciences innovation awardsOverall immunology solution

Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023

Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesWendy liExchange commissionAmerican society of hematologyFierce life sciences innovationGracell biotechnologies incAmerican society for hematologyInternational staging systemAmerican societyAnnual meetingChief medicalRevised international staging systemInvestigational new drugBiotech innovationLife sciences innovation awards

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells.

United statesWilliam caoDrug administrationExchange commissionGracell biotechnologies incFierce life sciences innovationInvestigational new drugChief executive officerAmerican societyHematology annual meetingBiotech innovationLife sciences innovation awardsOverall immunology solutionBiotech breakthrough awardsPrivate securities litigation reform act

Earnings call: PolyPid s Q3 2023 financial results show decreased expenses and progress in SHIELD II trial By Investing com

Earnings call: PolyPid s Q3 2023 financial results show decreased expenses and progress in SHIELD II trial By Investing com
investing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investing.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaDikla czaczkes akselbradJonny missulawinRoy buchananRaghuram selvarajuTsour segalBalaji prasadExchange commissionAmerican college of surgeons clinical congressInternational journal of toxicologyIsraeli ministry of healthPolypid ltdSouth americaPro tipsChief executive officer

908 Devices Inc (NASDAQ:MASS) Q3 2023 Earnings Call Transcript

Operator: Hello and welcome to today s 908 Devices Third Quarter 2023 Financial Results Conference Call. My name is Jordan and I ll be coordinating your call today.

University of massachusettsUnited statesMatt larewJoe griffithKevin knoppLuca fornelliWilliam blairSteven mahJoseph griffithKelly guraUniversity of oklahomaNational guardUs airUs department of defenseAmerican thoracic societyUs army